• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A v

tetano

Editor, Senior Moderator
Mucosal Immunol. 2018 Mar 15. doi: 10.1038/s41385-018-0017-4. [Epub ahead of print]
[h=1]IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses.[/h] Lapuente D[SUP]1,[/SUP][SUP]2[/SUP], Storcksdieck Genannt Bonsmann M[SUP]1[/SUP], Maaske A[SUP]1[/SUP], Stab V[SUP]1[/SUP], Heinecke V[SUP]1[/SUP], Watzstedt K[SUP]1[/SUP], He? R[SUP]1[/SUP], Westendorf AM[SUP]3[/SUP], Bayer W[SUP]4[/SUP], Ehrhardt C[SUP]5[/SUP], Tenbusch M[SUP]6,[/SUP][SUP]7[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] A universal influenza vaccine must provide protection against antigenically divergent influenza viruses either through broadly neutralizing antibodies or cross-reactive T cells. Here, intranasal immunizations with recombinant adenoviral vectors (rAd) encoding hemagglutinin (HA) and nucleoprotein (NP) in combination with rAd-Interleukin-(IL)-1β or rAd-IL-18 were evaluated for their efficacy in BALB/c mice. Mucosal delivery of rAd-IL-1β enhanced HA-specific antibody responses including strain-specific neutralizing antibodies. Nevertheless, the beneficial effects on the local T cell responses were much more impressive reflected by increased numbers of CD103[SUP]+[/SUP]CD69[SUP]+[/SUP] tissue-resident memory T cells (T[SUB]RM[/SUB]). This increased immunogenicity translated into superior protection against infections with homologous and heterologous strains including H1N1, pH1N1, H3N2, and H7N7. Inhibition of the egress of circulating T cells out of the lymph nodes during the heterologous infection had no impact on the degree of protection underscoring the unique potential of T[SUB]RM[/SUB] for the local containment of mucosal infections. The local co-expression of IL-1β and antigen lead to the activation of critical checkpoints in the formation of T[SUB]RM[/SUB] including activation of epithelial cells, expression of chemokines and adhesion molecules, recruitment of lung-derived CD103[SUP]+[/SUP] DCs, and finally local T[SUB]RM[/SUB] imprinting. Given the importance of T[SUB]RM[/SUB]-mediated protection at mucosal barriers, this study has major implications for vaccine development.


PMID: 29545648 DOI: 10.1038/s41385-018-0017-4
 
Back
Top Bottom